| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNJ16 |
| Uniprot No | Q9NPI9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-418aa |
| 氨基酸序列 | MSYYGSSYHIINADAKYPGYPPEHIIAEKRRARRRLLHKDGSCNVYFKHIFGEWGSYVVDIFTTLVDTKWRHMFVIFSLSYILSWLIFGSVFWLIAFHHGDLLNDPDITPCVDNVHSFTGAFLFSLETQTTIGYGYRCVTEECSVAVLMVILQSILSCIINTFIIGAALAKMATARKRAQTIRFSYFALIGMRDGKLCLMWRIGDFRPNHVVEGTVRAQLLRYTEDSEGRMTMAFKDLKLVNDQIILVTPVTIVHEIDHESPLYALDRKAVAKDNFEILVTFIYTGDSTGTSHQSRSSYVPREILWGHRFNDVLEVKRKYYKVNCLQFEGSVEVYAPFCSAKQLDWKDQQLHIEKAPPVRESCTSDTKARRRSFSAVAIVSSCENPEETTTSATHEYRETPYQKALLTLNRISVESQM |
| 预测分子量 | 1-418aa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCNJ16重组蛋白的参考文献示例(注：以下内容为模拟虚构，实际文献需通过学术数据库检索确认)：
1. **文献名称**：*Functional Characterization of Recombinant KCNJ16 Potassium Channels in Xenopus Oocytes*
**作者**：Smith A, et al.
**摘要**：本研究在非洲爪蟾卵母细胞中表达了重组KCNJ16蛋白，通过双电极电压钳技术分析其电生理特性，证实其形成pH敏感的内向整流钾通道，并揭示其在肾脏远端小管钾离子稳态中的潜在作用。
2. **文献名称**：*Structural and Functional Analysis of KCNJ16 Recombinant Protein via Cryo-Electron Microscopy*
**作者**：Zhang L, et al.
**摘要**：利用昆虫细胞系统表达并纯化KCNJ16重组蛋白，结合冷冻电镜解析其高分辨率结构，发现其胞内结构域与ATP结合的调控机制，为开发靶向钾通道的药物提供结构基础。
3. **文献名称**：*Co-expression of KCNJ16 and KCNJ15 Recombinant Proteins Modulates Inward Rectifier Currents in HEK293 Cells*
**作者**：Wang Y, et al.
**摘要**：在HEK293细胞中共表达KCNJ16和KCNJ15重组蛋白，发现两者形成异源四聚体通道，其电导特性显著不同于同源通道，提示其在肾小管钾离子分泌中的协同调控功能。
4. **文献名称**：*Role of KCNJ16 Mutants in Hypokalemia: Insights from Recombinant Channel Studies*
**作者**：Kim H, et al.
**摘要**：通过构建KCNJ16基因突变体重组蛋白，研究其通道功能异常与低钾血症的关联，发现特定突变导致通道活性降低，可能通过干扰肾髓质钾再吸收参与疾病发生。
---
**备注**：若需真实文献，建议通过PubMed或Google Scholar检索关键词“KCNJ16 recombinant protein”或“KCNJ16 expression”，并筛选涉及重组表达、功能或结构研究的文章。
KCNJ16. also known as Kir5.1. is a member of the inwardly rectifying potassium (Kir) channel family, which plays critical roles in maintaining cellular membrane potential and regulating electrolyte balance. Encoded by the *KCNJ16* gene, this protein forms tetrameric channels permeable to potassium ions. Structurally, Kir5.1 contains two transmembrane domains flanking a pore-forming region and a cytoplasmic N- and C-terminus. Unlike other Kir channels, Kir5.1 often functions as a heteromeric channel, primarily partnering with Kir4.1 (KCNJ10) to form Kir4.1/Kir5.1 complexes. These complexes are widely expressed in tissues such as the kidneys, inner ear, and brain, where they contribute to potassium homeostasis, fluid secretion, and neuronal excitability.
In the kidneys, Kir5.1 is localized to the distal nephron and is essential for regulating renal tubular potassium handling and acid-base balance. Dysfunction of Kir5.1 has been linked to electrolyte imbalances, hypertension, and renal tubular acidosis. In the inner ear, it helps maintain endolymphatic potential, crucial for hearing. Additionally, Kir5.1 modulates insulin secretion in pancreatic β-cells and influences central respiratory rhythms in the brainstem.
Recombinant KCNJ16 protein is produced using expression systems like *E. coli* or mammalian cell lines (e.g., HEK293) to study its biophysical properties, regulatory mechanisms, and interactions with partners such as Kir4.1. This protein is vital for structural analyses (e.g., cryo-EM), drug screening for channel modulators, and investigating disease-associated mutations. Studies using recombinant Kir5.1 have provided insights into its role in pathologies like EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) and diabetic nephropathy. Its recombinant form also aids in developing targeted therapies for channelopathies affecting renal, auditory, and neurological functions.
×
